

**AMENDMENTS TO THE SPECIFICATION**

This listing of amended paragraphs will replace all prior versions of the paragraphs in the application:

Please replace the second full paragraph on page 2, lines 13-22, with the amended paragraph:

-- The present invention provides benzamide-thiazolyl compounds, useful as kinase inhibitors, in particular, as inhibitors of p38 kinase. Thiazolyl derivatives that reportedly inhibit p38 kinase and TNF- $\alpha$  for use in treating inflammatory diseases are disclosed in WO 01/74811 and WO 01/10865 to Takeda Chem. Indus., WO 01/35959 to Astrazeneca AB, and ~~WO 01/17175~~ WO 02/096905 to Vertex Pharmaceuticals. Tyrosine kinase inhibitors having a thiazolyl component are disclosed in WO 02/45652 to Merck & Co., Inc., and WO 00/62778 to Bristol-Myers Squibb Company. Aminothiazolyl compounds useful as cyclin dependent kinase inhibitors are described in US Pat. No. 6,262,096 to Bristol-Myers Squibb Company. --